The Global Burden of Disease (GBD) Study provides an annually updated resource to study disease-related morbidity and mortality worldwide. Here we present the burden estimates for atopic dermatitis (AD), including …
Randomised controlled trial of topical corticosteroid and home-based narrowband UVB for active and limited vitiligo – results of the HI-Light Vitiligo trial.
Evidence for the effectiveness of vitiligo treatments is limited.To determine effectiveness of (a) hand-held narrowband-UVB (NB-UVB) and (b) combination of potent topical corticosteroid (TCS) and NB-UVB compared to TCS, for …
Anti-drug antibodies to TNF inhibitors in hidradenitis suppurativa: a systematic review.
Hidradenitis suppurativa (HS) is a chronic inflammatory condition which affects apocrine gland-rich skin.1 It primarily develops in intertriginous areas, including the axilla, groin, perianal, and perineal regions and presents with …
Laser therapy is a safe and effective treatment for unwanted hair in adults undergoing male to female sex reassignment.
Reduction in unwanted facial and body hair is an important goal in the process of sex reassignment. Laser treatment is a well-established, effective, popular and safe method of reducing unwanted …
SARS-CoV-2 Has Not Been Detected Directly by Electron Microscopy in the Endothelium of Chilblain Lesions: reply from authors.
We fully agree that the interpretation of electron microscopy findings can be challenging, even for experts. Differences between viral pathogens and normal subcellular organelles may be subtle, and some cellular …
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early …
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.
Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, a key driver of atopic dermatitis (AD).To evaluate the efficacy and safety of tralokinumab in combination with TCS in …
QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study.
Tuberculosis (TB) screening is mandatory for psoriasis biologic treatment. However, evidences regarding TB screening results during biologic treatment are conflicting.The aim of this study is to evaluate the rate of …
A clinical and histological comparison between acute cutaneous graft-versus-host disease and other maculopapular eruptions following hematopoietic stem cell transplantation: a retrospective cohort.
Prompt management of acute graft-versus-host disease (GVHD) may prevent its morbidity and mortality. Maculopapular (MP) eruption is a presenting sign of acute GVHD, but differentiation from other causes of MP …
Direct immunofluorescence findings in livedoid vasculopathy: A 10-year study and literature review.
Direct immunofluorescence (DIF) findings in patients with livedoid vasculopathy (LV) may have benefits.To investigate DIF findings in patients with a clinical and histopathological diagnosis of LV.DIF findings of 62 LV …